JPWO2021150673A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021150673A5 JPWO2021150673A5 JP2022544753A JP2022544753A JPWO2021150673A5 JP WO2021150673 A5 JPWO2021150673 A5 JP WO2021150673A5 JP 2022544753 A JP2022544753 A JP 2022544753A JP 2022544753 A JP2022544753 A JP 2022544753A JP WO2021150673 A5 JPWO2021150673 A5 JP WO2021150673A5
- Authority
- JP
- Japan
- Prior art keywords
- ethoxy
- glu
- amino
- acetyl
- carboxyphenoxy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062964932P | 2020-01-23 | 2020-01-23 | |
| US62/964,932 | 2020-01-23 | ||
| PCT/US2021/014302 WO2021150673A1 (en) | 2020-01-23 | 2021-01-21 | Gip/glp1 co-agonist compounds |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025195273A Division JP2026069790A (ja) | 2020-01-23 | 2025-11-14 | Ｇｉｐ／ｇｌｐ１共アゴニスト化合物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023511441A JP2023511441A (ja) | 2023-03-17 |
| JP2023511441A5 JP2023511441A5 (https=) | 2024-01-25 |
| JPWO2021150673A5 true JPWO2021150673A5 (https=) | 2024-01-25 |
Family
ID=74592824
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022544753A Pending JP2023511441A (ja) | 2020-01-23 | 2021-01-21 | Ｇｉｐ／ｇｌｐ１共アゴニスト化合物 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20230265151A1 (https=) |
| EP (1) | EP4093757A1 (https=) |
| JP (1) | JP2023511441A (https=) |
| KR (1) | KR20220131292A (https=) |
| CN (1) | CN115298207A (https=) |
| AR (1) | AR121093A1 (https=) |
| AU (1) | AU2021211451B2 (https=) |
| BR (1) | BR112022014397A2 (https=) |
| CA (1) | CA3165430A1 (https=) |
| IL (1) | IL294955A (https=) |
| MX (1) | MX2022009149A (https=) |
| TW (1) | TWI770781B (https=) |
| WO (1) | WO2021150673A1 (https=) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI912614B (zh) * | 2017-12-21 | 2026-01-21 | 美商美國禮來大藥廠 | 腸促胰島素(incretin)類似物及其用途 |
| WO2022159395A1 (en) | 2021-01-20 | 2022-07-28 | Viking Therapeutics, Inc. | Compositions and methods for the treatment of metabolic and liver disorders |
| JP2024508745A (ja) * | 2021-02-17 | 2024-02-28 | イーライ リリー アンド カンパニー | Ｇｉｐ／ｇｌｐ１デュアルアゴニスト治療方法 |
| IL310377A (en) | 2021-08-30 | 2024-03-01 | Mindrank Ai Ltd | Novel aryl ether substituted heterocyclic compound as glp1r agonist |
| MX2024003236A (es) | 2021-09-15 | 2024-06-19 | Viking Therapeutics Inc | Composiciones y metodos para el tratamiento de trastornos metabolicos y hepaticos. |
| CN117586373A (zh) * | 2022-08-10 | 2024-02-23 | 成都奥达生物科技有限公司 | 一种长效双激动剂化合物 |
| CN116023444B (zh) * | 2022-08-12 | 2023-08-01 | 重庆宸安生物制药有限公司 | 一种gip和glp-1双受体激动剂多肽化合物及其应用 |
| WO2024165571A2 (en) | 2023-02-06 | 2024-08-15 | E-Therapeutics Plc | Inhibitors of expression and/or function |
| WO2025125576A2 (en) | 2023-12-15 | 2025-06-19 | E-Therapeutics Plc | Inhibitors of expression and/or function |
| WO2025133348A1 (en) | 2023-12-22 | 2025-06-26 | E-Therapeutics Plc | Inhibitors of expression and/or function |
| EP4686757A1 (en) | 2024-07-31 | 2026-02-04 | e-therapeutics PLC | Inhibitors of expression and/or function |
| WO2025196502A1 (en) | 2024-03-20 | 2025-09-25 | North Carolina Agricultural & Technical State University | Choline kinase inhibitors as a therapeutic treatment for obesity |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR080592A1 (es) * | 2010-03-26 | 2012-04-18 | Lilly Co Eli | Peptido con actividad para el gip-r y glp-1-r, formulacion famaceutica que lo comprende, su uso para preparar un medicamento util para el tratamiento de diabetes mellitus y para inducir la perdida de peso |
| WO2012167744A1 (en) * | 2011-06-10 | 2012-12-13 | Beijing Hanmi Pharmaceutical Co., Ltd. | Glucose dependent insulinotropic polypeptide analogs, pharmaceutical compositions and use thereof |
| JP6228187B2 (ja) * | 2012-05-03 | 2017-11-08 | ジーランド ファーマ アクティーゼルスカブ | Ｇｉｐ−ｇｌｐ−１デュアルアゴニスト化合物及び方法 |
| HK1211232A1 (en) * | 2012-12-21 | 2016-05-20 | Sanofi | Exendin-4 derivatives as dual glp1/gip or trigonal glp1/gip/glucagon agonists |
| MX2016005556A (es) * | 2013-11-06 | 2016-07-15 | Zealand Pharma As | Compuestos agonistas duales de gip-glp-1 y procedimientos. |
| JO3575B1 (ar) | 2015-01-09 | 2020-07-05 | Lilly Co Eli | مركبات مساعد مشترك من gip وglp-1 |
| TWI783244B (zh) * | 2015-06-22 | 2022-11-11 | 美商美國禮來大藥廠 | 升糖素及glp-1共激動劑化合物 |
| TWI767095B (zh) * | 2017-12-21 | 2022-06-11 | 美商美國禮來大藥廠 | 腸促胰島素(incretin)類似物及其用途 |
| CN112469731B (zh) * | 2018-07-23 | 2024-11-29 | 伊莱利利公司 | Gip/glp1共激动剂化合物 |
-
2021
- 2021-01-21 WO PCT/US2021/014302 patent/WO2021150673A1/en not_active Ceased
- 2021-01-21 AR ARP210100135A patent/AR121093A1/es unknown
- 2021-01-21 EP EP21705072.3A patent/EP4093757A1/en active Pending
- 2021-01-21 JP JP2022544753A patent/JP2023511441A/ja active Pending
- 2021-01-21 US US17/794,128 patent/US20230265151A1/en active Pending
- 2021-01-21 AU AU2021211451A patent/AU2021211451B2/en active Active
- 2021-01-21 IL IL294955A patent/IL294955A/en unknown
- 2021-01-21 TW TW110102332A patent/TWI770781B/zh active
- 2021-01-21 BR BR112022014397A patent/BR112022014397A2/pt unknown
- 2021-01-21 CA CA3165430A patent/CA3165430A1/en active Pending
- 2021-01-21 MX MX2022009149A patent/MX2022009149A/es unknown
- 2021-01-21 KR KR1020227028667A patent/KR20220131292A/ko not_active Withdrawn
- 2021-01-21 CN CN202180023819.8A patent/CN115298207A/zh active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPWO2021150673A5 (https=) | ||
| TWI700291B (zh) | 升糖素及glp-1共激動劑化合物 | |
| DK1797109T3 (en) | MIXTURES OF POLYPEPTIDES, compositions containing them and methods for their preparation, and uses thereof | |
| JP2022095872A5 (https=) | ||
| AU2022311814A1 (en) | Lipidated peptide inhibitors of interleukin-23 receptor | |
| US10548952B2 (en) | Injectable solution at pH7 comprising at least one basal insulin the pI of which is from 5.8 to 8.5, a prandial insulin and/or a gastrointestinal hormone, and a co-polyamino acid bearing carboxylate charges and hydrophobic radicals | |
| EP2427475B1 (en) | High penetration prodrug compositions of peptides and peptide-related compounds | |
| CN116710462A (zh) | 用于治疗代谢病症和肝病的组合物和方法 | |
| TW202321275A (zh) | 介白素—２３受體之雙環肽抑制劑 | |
| CN103998063A (zh) | 聚乙二醇基肾上腺髓质素前药及其用途 | |
| US20160375135A1 (en) | Phenylalkylcarboxylic acid delivery agents | |
| JP2025134881A (ja) | Ｓａｒｓの治療のための化合物 | |
| JP2025118775A5 (https=) | ||
| WO2017180535A1 (en) | Chiral peptides | |
| JP2022513176A (ja) | オキシントモジュリンペプチド類似体製剤 | |
| CN101631558A (zh) | 基于艾塞那肽和达拉根的用于治疗糖尿病的药物、其用途和治疗模式 | |
| CN118108832A (zh) | 一种长效的类似胰淀素的多肽衍生物及其制备方法和用途 | |
| EP3094643B1 (en) | Lipidated peptides for lowering blood glucose | |
| TW201127387A (en) | Therapeutic or preventive agents for diabetes | |
| CN100372533C (zh) | 腹泻为主大肠激惹综合征的治疗制剂 | |
| JPWO2019246225A5 (https=) | ||
| CN119156396A (zh) | 用于治疗covid感染的方法和组合物 | |
| JPWO2021023817A5 (https=) | ||
| JPH1017491A (ja) | 慢性線維形成肝疾患および急性肝疾患の治療のための薬剤の製造におけるブラジキニンアンタゴニストの使用 | |
| JP7711088B2 (ja) | Ｓａｒｓの治療のための化合物 |